An open-label study to assess the efficacy and safety of extended TARPEYO® (delayed-release budesonide capsules) treatment in adult patients with primary IgA nephropathy who have completed 9 months of TARPEYO® 16 mg once daily treatment in real-world clinical practice
To investigate the efficacy of extended TARPEYO treatment in adults with IgAN.
Why this Research Matters
TARPEYO 16mg once daily for 6 months, TARPEYO 8mg once daily for 9 months, and TARPEYO 4 mg daily for 2 weeks of tapering.
Who can Participate
Adult
IgAN diagnosis confirmed by biopsy; age 18 yo or older; completion of 9 months of commercial treatment with TARPEYO proteinuria greater than or equal to 0.5 g/day or UPCR greater than or equal to 0.3 g/gram during screening; on stable RAS inhibitor therapy for at least 8 weeks.
Study ID
Protocol Number: 25-0249
Meet the Team
Principal Investigator